• Skip to primary navigation
  • Skip to main content
  • Skip to footer
ppi_logo_rgb_outlinedv3
address
  • Home
  • About
    • Introduction
    • PPi’s 20th Anniversary
    • The Strength of PPI HC
    • Our Mission
    • Global Reach
    • Customers
    • Team
    • Gallery
  • Services
    • Landscape Assessments
    • Market Access Strategy
    • Research and Insights
    • Pricing Strategy
    • Reimbursement Strategy
    • Health Technology Assessment dossiers
    • Health Economics
    • Orphan & Rare Diseases
  • Communications
    • Case Studies
    • Publications
    • Conferences
  • Contact
  • Home
  • About
    • Introduction
    • PPi’s 20th Anniversary
    • The Strength of PPI HC
    • Our Mission
    • Global Reach
    • Customers
    • Team
    • Gallery
  • Services
    • Landscape Assessments
    • Market Access Strategy
    • Research and Insights
    • Pricing Strategy
    • Reimbursement Strategy
    • Health Technology Assessment dossiers
    • Health Economics
    • Orphan & Rare Diseases
  • Communications
    • Case Studies
    • Publications
    • Conferences
  • Contact

Case Studies

Pricing, Early Access Strategy and Launch planning

  1. Home>
  2. category>
  3. Communications>
  4. Case Studies>
Pricing, Early Access Strategy and Launch planning

Objectives: To assess opportunities for pre-approval use (PAU/early access) and pricing

Therapy Area: Severe hepatic veno-occlusive disease

Client: USA pharma company

Product/Technology: Drug

Scope: 8 countries (EU5, Japan, Australia, S.Korea)

Our Workplan: Developed workplan based on secondary research to explore potential commercialisation and regulatory issues in order to assess in which countries PAU may be possible, at what price level and what the associated considerations would be.

Project Duration: 10 weeks

Outcome: Report summarising findings and recommendations + results presentation meeting. 1 year after report submitted, client contacted us to pass on their heartfelt thanks as the course of action and programme that we recommended had been a tremendous success, making a huge difference for the company, which had now achieved sales of $2.5m on the back of our recommendations. They had reviewed our report to compare what we said would happen with what had actually happened, and our team was 100% correct!

Case Studies

  • Pricing, Early Access Strategy and Launch planning
  • Value and Access Strategy
  • Pricing, Reimbursement and Launch Planning Strategy
  • P&R Due Diligence Assessment for 2 agents
  • COPD Payer research
  • International Reimbursement planning
  • European P&R planning

TESTIMONIALS

“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

Filed Under: Case Studies

Value and Access Strategy

  1. Home>
  2. category>
  3. Communications>
  4. Case Studies>
Value and Access Strategy

Objectives: To advise on such as clinical programme, reimbursement needs, market access, representational and distribution issues for a novel technology

Therapy Area: Amyotrophic Lateral Sclerosis (ALS)

Client: USA pharma company

Product/Technology: Drug

Scope: 9 countries (Spain, France, Germany, Swe, Ita, NL, UK, Brazil, Australia)

Our Workplan: Primary research with n=36 in market clinical and payer stakeholders using a developed Product Profile explaining the technology and draft clinical protocol, and a core Discussion Guide adapted for the different territories

Project Duration: 13 weeks

Outcome: Guidance provided on all pertinent issues including on clinical programme design and appropriate QoL instrument for clinical study, DRG (diagnosis related groups) issues and actions, price guidance, specific reimbursement processes and activities and suggested in-market prelaunch activities.

Case Studies

  • Pricing, Early Access Strategy and Launch planning
  • Value and Access Strategy
  • Pricing, Reimbursement and Launch Planning Strategy
  • P&R Due Diligence Assessment for 2 agents
  • COPD Payer research
  • International Reimbursement planning
  • European P&R planning

TESTIMONIALS

“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

Filed Under: Case Studies

Pricing, Reimbursement and Launch Planning Strategy

  1. Home>
  2. category>
  3. Communications>
  4. Case Studies>
Pricing, Reimbursement and Launch Planning for Orphan Drug

Objectives: To develop pricing and reimbursement (P&R) strategy, assess pre-approval use possibilities and identify any specific local issues

Therapy Area: Orphan inherited disease (mucopolysaccharidosis)

Client: USA Biopharmaceutical company

Product/Technology: Drug

Scope: 15 European countries

Our Workplan: Developed product profile and discussion guide followed by Key Opinion Leader (KOL) and payer discussions in each territory

Project Duration: 12 weeks

Outcome: Provided report and summary presentation of findings/recommendations including in-market and international pricing strategy, optimal launch sequence, reimbursement data needs, identifying main likely treatment centres and markets where a pre-approval use availability was advocated. Full international team attended results presentation meeting.

Case Studies

  • Pricing, Early Access Strategy and Launch planning
  • Value and Access Strategy
  • Pricing, Reimbursement and Launch Planning Strategy
  • P&R Due Diligence Assessment for 2 agents
  • COPD Payer research
  • International Reimbursement planning
  • European P&R planning

TESTIMONIALS

“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

Filed Under: Case Studies

P&R Due Diligence Assessment for 2 agents

  1. Home>
  2. category>
  3. Communications>
  4. Case Studies>
Pricing, Reimbursement andLaunch Planning Strategy

Objectives: To assess the prospective pricing and reimbursement (P&R) environment for 2 novel formulation drugs to support client’s decision whether to in-licence the products

Therapy Areas: Antiemetic and antifungal

Client: UK pharma company

Product/Technology: Drugs

Scope: UK, Germany, France, Spain, Italy and Netherlands

Our Workplan: Compared agents with appropriate comparator agents and P&R proxies for novel formulation drugs and considered relevant state P&R regulations

Project Duration: 13 days

Outcome: Analysis recommended favourable P&R environment for both agents and advocated proceeding with in-licence. Also guidance provided for necessary clinical programmes and data needs to achieve optimal P&R.

Case Studies

  • Pricing, Early Access Strategy and Launch planning
  • Value and Access Strategy
  • Pricing, Reimbursement and Launch Planning Strategy
  • P&R Due Diligence Assessment for 2 agents
  • COPD Payer research
  • International Reimbursement planning
  • European P&R planning

TESTIMONIALS

“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

Filed Under: Case Studies

COPD Payer research

  1. Home>
  2. category>
  3. Communications>
  4. Case Studies>
COPD Payer research

Objectives: Payer research to assess unmet needs in COPD, perceptions of current therapeutic approaches, evidence requirements, attractive value propositions and market access considerations

Therapy Area: COPD (mild/moderate/severe)

Client: USA pharma company

Product/Technology: Drug

Scope: 7 countries (UK, US, Can, Aus, Swe, Fra, Ger)

Our Workplan: Developed multi-country discussion guides and recruited and interviewed senior payers and payer advisors

Project Duration: 14 weeks

Outcome: Key output was a 109 slide presentation detailing our findings per market and drawing cross-market inferences. Analysis included a ranking of importance for many of the aspects investigated (type of data required, design of clinical study, choice of primary endpoint and mechanisms of outcome measurement etc.) as well as a prospective evaluation of how needs and expectations would change over the next few years.

Case Studies

  • Pricing, Early Access Strategy and Launch planning
  • Value and Access Strategy
  • Pricing, Reimbursement and Launch Planning Strategy
  • P&R Due Diligence Assessment for 2 agents
  • COPD Payer research
  • International Reimbursement planning
  • European P&R planning

TESTIMONIALS

“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

Filed Under: Case Studies

  • Page 1
  • Page 2
  • Go to Next Page »
PPI Logo

Adding global value through local expertise and insight

Adding global value through local expertise and insight

PPi Healthcare Consulting Ltd
5 The Chambers, Vineyard
Abingdon-on-Thames
Oxfordshire
OX14 3PX, UK

Further information:
E: info@ppi.consulting
T: +44 (0)7811 363098

Privacy Policy

GEP

© copyright 2020
PPi Healthcare Consulting Ltd
All rights reserved

This website uses cookies to improve your experience. To view our privacy policy click here. To change your cookie preferences:Cookie settingsor ACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT